Login / Signup

Immunosuppressors and immunomodulators in Neurology - Part I: a guide for management of patients underimmunotherapy.

Fabiano Ferreira de AbrantesMarianna Pinheiro Moraes de MoraesJosé Marcos Vieira de Albuquerque FilhoJéssica Monique Dias AlencarAlexandre Bussinger LopesWladimir Bocca Vieira de Resende PintoPaulo Victor Sgobbi de SouzaEnedina Maria Lobato de OliveiraAcary de Souza Bulle de OliveiraJosé Luiz PedrosoOrlando Grazianni Povoas Barsottini
Published in: Arquivos de neuro-psiquiatria (2021)
For patients with autoimmune diseases, the risks and benefits of immunosuppressive or immunomodulatory treatment are a matter of continual concern. Knowledge of the follow-up routine for each drug is crucial, in order to attain better outcomes and avoid new disease activity or occurrence of adverse effects. To achieve control of autoimmune diseases, immunosuppressive and immunomodulatory drugs act on different pathways of the immune response. Knowledge of the mechanisms of action of these drugs and their recommended doses, adverse reactions and risks of infection and malignancy is essential for safe treatment. Each drug has a specific safety profile, and management should be adapted for different circumstances during the treatment. Primary prophylaxis for opportunistic infections and vaccination are indispensable steps during the treatment plan, given that these prevent potential severe infectious complications. General neurologists frequently prescribe immunosuppressive and immunomodulatory drugs, and awareness of the characteristics of each drug is crucial for treatment success. Implementation of a routine before, during and after use of these drugs avoids treatment-related complications and enables superior disease control.
Keyphrases
  • immune response
  • emergency department
  • rheumatoid arthritis
  • type diabetes
  • risk factors
  • toll like receptor
  • early onset
  • weight loss
  • quality improvement
  • adverse drug
  • juvenile idiopathic arthritis